Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20531674 | 1.00 | DGAT1 (0.38) | DGAT1PDE10AKDM4EALOX15L3MBTL1 | |
| SCHEMBL20531562 | 1.00 | DGAT1 (0.38) | DGAT1PDE10AKDM4EALOX15L3MBTL1 | |
| SCHEMBL3538703 | 0.87 | DGAT1 (0.39) | DGAT1PDE10AKLKB1MAPT | |
| SCHEMBL19780155 | 0.83 | DGAT1 (0.57) | DGAT1L3MBTL1KLKB1 | |
| SCHEMBL20531461 | 0.83 | DGAT1 (0.57) | DGAT1L3MBTL1KLKB1 | |
| SCHEMBL15315928 | 0.80 | PDE10A (0.39) | DGAT1PDE10AKDM4EKLKB1 | |
| SCHEMBL23620257 | 0.79 | DGAT1 (0.41) | DGAT1PDE10AKLKB1MAPT | |
| SCHEMBL2553654 | 0.79 | DGAT1 (0.41) | DGAT1KLKB1MAPT | |
| SCHEMBL9958472 | 0.79 | PDE10A (0.35) | DGAT1PDE10A | |
| SCHEMBL9958473 | 0.79 | PDE10A (0.35) | DGAT1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-12-23 | — | — | US | disclosed |
| US-10781200-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-10301284-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-05-28 | — | — | US | disclosed |
| WO-2018011628-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239435-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | DGAT1 2183/4885PDE10A 1883/4885KDM4E 798/4885 |
| US-20210395221-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | DGAT1 2183/4885PDE10A 1883/4885KDM4E 798/4885 |
| US-10781200-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | DGAT1 2183/4885PDE10A 1883/4885KDM4E 798/4885 |
| US-10301284-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | DGAT1 2183/4885PDE10A 1883/4885KDM4E 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.